News release  

DCL’S Liquid-Stable Microalbumin Assay  
Receives FDA Clearance For Human Testing

Oxford, CT . . . Diagnostic Chemicals Limited (DCL) has announced that its two-part, liquid-stable Microalbumin assay has received FDA 510(k) clearance for the quantitative determination of the analyte in urine.  The availability of this new assay will serve as a useful clinical tool in the diagnosis and treatment of diabetes and kidney disease and will serve to benefit all clinical laboratories.

DCL’s Microalbumin assay employs an immunoturbidimetric test method, while offering exemplary performance characteristics with regard to accuracy, precision and linearity.  Optimized for use on a variety of instrument platforms, DCL's Microalbumin assay is perfectly suited for use with fully automated testing procedures, with an extensive listing of applications readily available.

Offered in a compact packaging format, the test kit provides clinical laboratories with a configuration that is well suited for existing instrumentation and workflow requirements.  Separate quality control and calibration materials are also available to fully support the assay.

DCL serves the clinical chemistry, point-of-care/rapid testing, veterinary and life science markets with a comprehensive line of products.  For additional information, contact DCL at 160 Christian Street, Oxford, CT  06478.  Phone: 203-881-2020; Toll-Free: 800-325-2436; FAX: 203-888-1143; E-mail: sales@dclchem.com, or visit the DCL website at www.dclchem.com.

Please refer any requests for product information directly to:

Doug Borses
Technical Marketing Manager
Diagnostic Chemicals Limited
160 Christian Street
Oxford, CT 06478

Tel: 800-325-2436
FAX: 203-888-1143

E-Mail: dborses@dclchem.com